Share the post "Sun Pharma Advanced Research Company announced Financial Results Q1 2024"
Highlights
- The presented financial data is Standalone to provide a comprehensive overview of the company performance.
- Sales over the Year and quarter: The company’s sales declined by -29.81 % over the year, substantial increase in net sales/revenue by 1.51 %.
- Income over the Year and quarter: There has been decline in other income over the past year which is -84.69 %, Marginal decrease of -64.55% in other income during this quarter.
- Profit over the Year and quarter: Significant improvement in profitability for Sun Pharma Advanced Research Company Limited. Notable increase of 1.56 % in net profit Year to Year, Sun Pharma Advanced Research Company Limited’s profitability dropped by -9.23 % Quarter to Quarter.
- EPS over the Year and quarter: EPS increased by 1.36 % Year to Year. EPS decreased by -9.42 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 23.95 Cr | Rs. 16.56 Cr | Rs. 16.81 Cr | + 1.51 % | -29.81 % |
| Expenses | Rs. 126.13 Cr | Rs. 124.08 Cr | Rs. 111.93 Cr | -9.79 % | -11.26 % |
| Operating Profit | Rs. -102.18 Cr | Rs. -107.52 Cr | Rs. -95.12 Cr | + 11.53 % | + 6.91 % |
| OPM % | -426.64 % | -649.28 % | -565.85 % | + 83.43 % | -139.21 % |
| Other Income | Rs. 10.19 Cr | Rs. 4.4 Cr | Rs. 1.56 Cr | -64.55 % | -84.69 % |
| Interest | Rs. 0.26 Cr | Rs. 0.88 Cr | Rs. 0.52 Cr | -40.91 % | + 100 % |
| Depreciation | Rs. 3.1 Cr | Rs. 2.69 Cr | Rs. 2.76 Cr | + 2.6 % | -10.97 % |
| Profit before tax | Rs. -95.35 Cr | Rs. -106.69 Cr | Rs. -96.84 Cr | + 9.23 % | -1.56 % |
| Tax % | -0 % | -0 % | -0 % | 0 % | 0 % |
| Net Profit | Rs. -95.35 Cr | Rs. -106.69 Cr | Rs. -96.84 Cr | + 9.23 % | -1.56 % |
| EPS in Rs | Rs. -2.94 | Rs. -3.29 | Rs. -2.98 | + 9.42 % | -1.36 % |
Today, we’re looking at Sun Pharma Advanced Research Company Limited’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -29.81 %. However, it did see a marginal increase of 1.51 % from the previous quarter. Expenses decreased slightly by -9.79 % quarter-on-quarter, aligning with the annual decline of -11.26 %. Operating profit, while up 6.91 % compared to last year, faced a quarter-on-quarter increase of 11.53 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -139.21 %, but an expansion of 83.43 % sequentially. Other income fell by -64.55 % compared to the last quarter, despite an annual decline of -84.69 %. Interest expenses dropped significantly by -40.91 % from the previous quarter, yet the year-over-year increase remains at a moderate 100 %. Depreciation costs climbed by 2.6 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -10.97 %. Profit before tax declined annually by -1.56 % but saw an increase from the preceding quarter by 9.23 %.
Net profit fell by -1.56 % year-on-year but experienced a 9.23 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -1.36 % but a quarterly rise of 9.42 %. In summary, Sun Pharma Advanced Research Company Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 23.95 Cr | Rs. 16.56 Cr | Rs. 16.81 Cr | + 1.51 % | -29.81 % |
| Expenses | Rs. 126.13 Cr | Rs. 124.08 Cr | Rs. 111.93 Cr | -9.79 % | -11.26 % |
| Operating Profit | Rs. -102.18 Cr | Rs. -107.52 Cr | Rs. -95.12 Cr | + 11.53 % | + 6.91 % |
| Net Profit | Rs. -95.35 Cr | Rs. -106.69 Cr | Rs. -96.84 Cr | + 9.23 % | -1.56 % |
| EPS in Rs | Rs. -2.94 | Rs. -3.29 | Rs. -2.98 | + 9.42 % | -1.36 % |
In reviewing Sun Pharma Advanced Research Company Limited’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -29.81 % year-on-year, however, there was a minor increase of 1.51 % from the previous quarter. Expenses decreased by -11.26 % compared to the previous year, with a decrease of -9.79 % quarter-on-quarter. Operating Profit surged by 6.91 % annually, and saw a 11.53 % increase from the last quarter.
Net Profit showed yearly decrease of -1.56 %, and experienced a 9.23 % increase from the previous quarter. Earnings Per Share (EPS) fell by -1.36 % annually, however rose by 9.42 % compared to the last quarter. In essence, while Sun Pharma Advanced Research Company Limited faces strong annual decline indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
[my_shortcode1 values=”Sun Pharma Advanced Research Company “]
